UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma

PloS one, 2015-09, Vol.10 (9), p.e0139073

2015

Volltextzugriff (PDF)

Sterbeort Hospiz

Deutsche Zeitschrift für Onkologie (Heidelberg, Germany : 2001), 2015-09, Vol.47 (3), p.1-3

2015

Volltextzugriff (PDF)

Dendritic cells fused with core binding factor‐beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes

British journal of haematology, 2004-08, Vol.126 (4), p.593-601

2004

Volltextzugriff (PDF)

Empirische Befunde zur Verlegungspraxis Sterbender

MMW Fortschritte der Medizin, 2017-10, Vol.159 (Suppl 6), p.6-14

2017

Volltextzugriff (PDF)

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study

Journal of clinical oncology, 2012-06, Vol.30 (18_suppl), p.3-3

2012

Volltextzugriff (PDF)

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3-3

2012

Volltextzugriff (PDF)

Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma: e0139073

PloS one, 2015-09, Vol.10 (9)

2015

Volltextzugriff (PDF)

Antigen loss variants of a murine renal cell carcinoma: Implications for tumor vaccination

International journal of cancer, 1998-07, Vol.77 (1), p.114-122

1998

Volltextzugriff (PDF)

Empirical findings concerning transfer of dying persons

MMW Fortschritte der Medizin, 2017-10, Vol.159 (Suppl 6), p.6

2017

Volltextzugriff (PDF)

Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma

Supportive care in cancer, 2007-07, Vol.15 (7), p.877-884

2007

Volltextzugriff (PDF)

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study

British journal of haematology, 2015-03, Vol.168 (6), p.824-834

2015

Volltextzugriff (PDF)

Rituximab combined with Dexa BEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study

British journal of haematology, 2015-03, Vol.168 (6), p.824-834

2015

Volltextzugriff (PDF)

Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice

Journal of immunotherapy, 2006-03, Vol.29 (2), p.175-187

2006

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(15)

Sprache

Englisch
(12)
Deutsch
(3)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma

Sterbeort Hospiz

Dendritic cells fused with core binding factor‐beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes

Empirische Befunde zur Verlegungspraxis Sterbender

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study

Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response

Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma: e0139073

Antigen loss variants of a murine renal cell carcinoma: Implications for tumor vaccination

Empirical findings concerning transfer of dying persons

Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study

Rituximab combined with Dexa BEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study

Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice

Suchergebnisse filtern